Sep 2026· Advances in Clinical and Experimental Medicine· Vol 35, pp. 0-0· 0 citations
Medicine
TL;DR
Individuals with medical backgrounds and those who received information about vaccination from their physician were more likely to receive the RSV vaccine during pregnancy and women vaccinated against other diseases were more likely to choose RSV vaccination.
Abstract
Background
Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract infections in infants, particularly among vulnerable groups such as preterm newborns and infants with underlying medical conditions. The approval of the RSVpreF vaccine for use during pregnancy offers a new strategy for reducing RSV-related morbidity in newborns.
Objectives
This study aimed to assess RSV vaccination coverage among pregnant women in Poland, identify factors influencing vaccine hesitancy, and evaluate knowledge regarding the benefits of RSV vaccination.
MATERIAL AND
Methods
A Computer-Assisted Web Interview (CAWI) survey was conducted among 668 respondents in Poland. An anonymous questionnaire consisting of 23 questions was distributed via social media platforms between July 25 and August 1, 2024. Participants were recruited through Facebook groups and Instagram and included women who had recently given birth or were currently pregnant.
Results
Respondents with medical backgrounds more frequently provided correct answers to questions regarding RSV than those without medical training. For example, when asked about methods of treating RSV infection, 109 medical professionals (74.15%) answered correctly, compared with 251 non-medical respondents (48.18%; p < 0.001). Individuals with medical backgrounds and those who received information about vaccination from their physician were more likely to receive the RSV vaccine during pregnancy. In addition, women vaccinated against other diseases, such as influenza and pertussis, were more likely to choose RSV vaccination.
Conclusions
Vaccination against RSV during pregnancy is an important strategy for protecting newborns against severe RSV infection and should be promoted as a public health measure. Our findings highlight the need for targeted educational initiatives and public health campaigns to increase awareness and improve vaccination coverage among pregnant women.
OBJECTIVES
Most of the clinical and economic burden of the respiratory syncytial virus (RSV) in pediatric populations is concentrated among infants aged <1 year. Since 2024, RSVpreF vaccine is available in France for the vaccination of pregnant women between 32 and 36 weeks of gestational age, from September to January...
Y. Fahfouhi, S. Fiévez, R. Cohen et al.· Vaccine· 0 citations
BACKGROUND
Respiratory syncytial virus (RSV) is a leading cause of infant hospitalization globally. On September 1, 2024, England introduced the bivalent RSVpreF vaccine for maternal immunization following trial evidence of safety and efficacy. However, real-world data on uptake, safety and effectiveness remain limited...
Genevieve Haddock, Melissa Ng, Thomas E. Johnson et al.· The Pediatric Infectious Dis...· 0 citations
Objective The Respiratory Syncytial Virus (RSV) vaccine has recently been introduced in Saudi Arabia for adults aged 60 and older. There are limited published studies on this topic in Saudi Arabia for this age group. This study aimed to assess RSV vaccine acceptance among older adults in the Al-Qassim region of Saudi A...
Moath Aljohani, Dawood Al-Oraini· Patient Preference and Adher...· 0 citations
RSV and bronchiolitis are major causes of hospitalizations and death among infants. The RSVpreF vaccine was approved and released in 2023 for pregnant women to prevent severe RSV in infants during their first RSV season. This is the first prenatal vaccine recommended since the COVID-19 vaccine was approved. Howev...
Corinne R. Thornton, S. Bhumbra· Journal of the Pediatric Inf...· 0 citations
The findings suggest that tailored, evidence-based vaccine communication during antenatal care is particularly relevant for women with lower educational attainment, as well as a significant demographic divide.
Katarzyna Hinca, J. Jassem-Bobowicz, Iwona Jańczewska et al.· Frontiers in Public Health· 0 citations
Respiratory syncytial virus (RSV) is a leading cause of pediatric respiratory infections. This systematic review and meta-analysis aims to estimate the in-hospital positivity among children in Europe post-COVID-19 and prior to the implementation of the recent RSV prophylactic strategies. A systematic search was conduct...
M. Berikopoulou, Danai K. Giavasoglou, Argyro Konstantopoulou et al.· Journal of Clinical Virology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.